Trastuzumab Biosimilar Market Segmentation:
Application Segment Analysis
Breast cancer is the dominating sub-segment that is projected to hold a global trastuzumab biosimilar market share of 72.4% by the end of the forecast period. The global assessment as per the World Health Organization, projected that the incidence of HER2+ breast cancer is poised to grow up to 3 million each year by 2037. The growth of breast cancer cases is expected to expand the demand for intervention through trastuzumab biosimilar and result in market growth. Meanwhile, the expansion of the medical coverage is the growth factor that advocates the application scope through higher accessibility for patients.
Product Type Segment Analysis
Injectable segment in trastuzumab biosimilar market is leading and is anticipated to hold a share of 68.4% by the end of 2037. Injectable biosimilars are cost-saving in nature and provide a higher safety and efficacy rate during the intervention stage. According to the study of the National Health Institute, more than 88% of the U.S. oncologists rely on the injectable product type for dosing control. As per the analysis of the Food and Drug Administration, injectable products are approximately 31% cheaper in comparison to the lyophilized powders. This results in higher market accessibility and robust growth for the address subsegment of the trastuzumab biosimilar market.
Our in-depth analysis of the global trastuzumab biosimilar market includes the following segments:
|
Segment |
Subsegment |
|
Product Type |
|
|
Application |
|
|
Distribution Channel |
|
